DUXA Inhibitors
DUXA inhibitors are chemicals that indirectly lead to the inhibition of the transcription factor DUXA through various signaling pathways. These compounds are not direct antagonists of DUXA but inhibit upstream regulators or signaling pathways that contribute to DUXA's functional state. Staurosporine, for example, inhibits PKC and could impede the phosphorylation of DUXA, which is necessary for its activity. Inhibition of mTOR by rapamycin negatively affects the cellular conditions that promote DUXA activity, while LY294002 and Wortmannin decrease PI3K/AKT signaling, which could lead to reduced regulation of DUXA through AKT-dependent mechanisms.
In addition to these, MEK inhibitors like U0126 and PD98059 target the MAPK pathway, which is implicated in the regulation of various transcription factors, potentially including DUXA. SB203580's inhibition of p38 MAPK could also decrease DUXA activity by altering the transcription factor landscape in response to stress. JNK pathway inhibition by SP600125 may affect stress-related transcription factor activity, thereby indirectly influencing DUXA. Src kinase inhibition by PP2 might reduce DUXA activity by preventing activation of associated signaling cascades. Moreover, proteasome inhibition by Bortezomib can stabilize IκB, reducing NF-κB activity, which might intersect with DUXA regulatory
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent kinase inhibitor known to inhibit a wide range of protein kinases. By inhibiting protein kinase C (PKC), which is involved in the activation of numerous proteins via phosphorylation, staurosporine can decrease the phosphorylation and thus the activity of DUXA, as DUXA function is predicated on its phosphorylation state. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically binds to FKBP12 and the resulting complex inhibits mTOR, a key regulator of protein synthesis and cell growth. Since DUXA is a transcription factor that is regulated by cellular growth signals, inhibition of mTOR by rapamycin would reduce the cellular conditions that favor DUXA's activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that blocks the PI3K/AKT pathway. Since AKT can phosphorylate and thereby regulate the activity of various transcription factors, inhibiting this pathway would likely reduce DUXA activity by preventing its phosphorylation and activation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream activators of ERK1/2 in the MAPK pathway. By inhibiting this pathway, U0126 can prevent the activation of transcription factors regulated by MAPK signaling, potentially reducing the activity of DUXA, which may be influenced by this signaling cascade. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is another MEK inhibitor that works similarly to U0126. It specifically blocks MEK activation, which in turn prevents the activation of MAPK/ERK pathway, thereby reducing the phosphorylation and activation of transcription factors that could include DUXA. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. This kinase is involved in the response to stress stimuli and cytokines. By inhibiting p38, SB203580 could decrease the activation of transcription factors that are regulated by stress signals, potentially including DUXA. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. By inhibiting PI3K, it reduces AKT activation, similar to LY294002, leading to decreased activation of downstream transcription factors, potentially including DUXA. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the MAPK signaling pathway. Inhibition of JNK can prevent the phosphorylation and activation of transcription factors that respond to stress and cytokine signals, which could include DUXA. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. Src kinases can activate several downstream signaling pathways, including those that lead to the activation of transcription factors. By inhibiting Src kinases, PP2 could reduce DUXA activation indirectly. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of IκB, an inhibitor of NF-κB. By stabilizing IκB, bortezomib can reduce NF-κB activity, which may be involved in the regulation of transcription factors, potentially reducing DUXA activity indirectly. | ||||||